Most patients with advanced penile cancer will have relapsed disease after cisplatin-based combination chemotherapy. Unfortunately, these patients have dismal outcomes with salvage chemotherapy, surgery, or radiation.
In this review we will discuss the available chemotherapy and targeted therapies for salvage second line systemic treatment for patients with penile cancer. We will also summarize the ongoing interventional clinical trials using immune and human papilloma virus-based therapies.
Urologic oncology. 2020 Sep 16 [Epub ahead of print]
Jad Chahoud, Monica Tamil, Andrea Necchi
Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL., Department of Internal Medicine, McGovern Medical School, Houston, TX., Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/32950396